Search Results - "Tercero, J.C"

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) by Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., Cameron, D.

“…Adjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial…”
Get full text

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study by Schöffski, P, Taron, M, Jimeno, J, Grosso, F, Sanfilipio, R, Casali, P.G, Cesne, A. Le, Jones, R.L, Blay, J.-Y, Poveda, A, Maki, R.G, Nieto, A, Tercero, J.C, Rosell, R

“…Abstract Aim Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair…”
Get full text

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series by Grosso, F., Sanfilippo, R., Virdis, E., Piovesan, C., Collini, P., Dileo, P., Morosi, C., Tercero, J.C., Jimeno, J., D'Incalci, M., Gronchi, A., Pilotti, S., Casali, P.G.

“…Trabectedin has been approved in Europe as second-line therapy for advanced soft tissue sarcomas. A previous analysis showed that myxoid liposarcomas (MLS) are…”
Get full text

943 Functional Consequences Mediated by the Inhibition of the Fanconi Anemia Pathway in Transformed Cells Treated With Anticancer Drugs of Marine Origin by Martínez, S, Pérez, L, Banos, R, Río, P, Casado, J.A, Galmarini, C, Aracil, M, Tercero, J.C, Albella, B, Bueren, J.A

Get full text

278 Myxoid liposarcoma tumors with different chimera subtypes xenografted in nude mice are characterized by different response to trabectedin and gene expression profile by Marchini, S, Frapolli, R, Nerini, I.F, Pilotti, S, Casali, P, Grosso, F, Sanfilippo, R, Gronchi, A, Tercero, J.C, D'incalci, M

Get full text

8005 Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs Trabectedin (T) + PLD in the ET743-OVA-301 clinical trial by Poveda, A, Kaye, S, Herzog, T, Ghatage, P, Meerpohl, H, Ngan, H, Emerich, J, Tercero, J.C, Ricci, D, Monk, B

Get full text

MAK3 encodes an N-acetyltransferase whose modification of the L-A gag NH2 terminus is necessary for virus particle assembly by TERCERO, J. C, WICKNER, R. B

“…The MAK3 gene is necessary for propagation of the L-A double-stranded RNA virus of Saccharomyces cerevisiae. MAK3 encodes a protein with substantial homology…”
Get full text

Localized mutagenesis and evidence for post-transcriptional regulation of MAK3: a putative N-acetyltransferase required for double-stranded RNA virus propagation in Saccharomyces cerevisiae by Tercero, J.C. (National Institutes of Health, Bethesda, MD), Riles, L.E, Wickner, R.B

“…The MAK3 gene of Saccharomyces cerevisiae is necessary for the propagation of the L-A double-stranded RNA virus and its satellites, such as M1 that encodes a…”
Get full text

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma by Gronchi, A., Bui, B.N., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R.J., Demetri, G.D., Le Cesne, A., Lardelli, P., Pérez, I., Nieto, A., Tercero, J.C., Alfaro, V., Tamborini, E., Blay, J.Y.

“…To evaluate neoadjuvant trabectedin (1.5 mg/m2 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML)…”
Get full text

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents by Uboldi, S., Bernasconi, S., Romano, M., Marchini, S., Fuso Nerini, I., Damia, G., Ganzinelli, M., Marangon, E., Sala, F., Clivio, L., Chiorino, G., Giandomenico, S. Di, Rocchi, M., Capozzi, O., Margison, G.P., Watson, A.J., Caccuri, A.M., Pastore, A., Fossati, A., Mantovani, R., Grosso, F., Tercero, J.C., Erba, E., D'Incalci, M.

“…Myxoid Liposarcomas (MLS), characterized by the expression of FUS‐CHOP fusion gene are clinically very sensitive to the DNA binding antitumor agent,…”
Get full text

479 Impact of the DNA repair efficiency in the outcome of sarcoma patients treated with ET-743 (Yondelis) by van Oosterom, A., Maki, R., Taron, M., Sciot, R., Fernandez Sousa-Faro, J.M., Tercero, J.C., Jimeno, J., Rosell, R.

Get full text

37 Sensitivity and resistance of human leukemic blasts to aplidin; molecular signature by gene expression profiling (GEP) by Martinez, N., Sanchez Beato, M., Kaspers, G., Fernandez, I., de la Cueva, P., Tercero, J.C., Jimeno, J., Piris, M.A.

Get full text

36 Transcriptional signature associated with sensitivity to ET-743 (Yondelis) in low passage sarcoma cell lines by Sanchez Beato, M., Martinez, N., Fernandez, I., Navarrete, M., de la Cueva, P., Carnero, A., Tercero, J.C., Jimeno, J., Piris, M.A.

Get full text

Yeast MAK3 N-acetyltransferase recognizes the N-terminal four amino acids of the major coat protein (gag) of the L-A double-stranded RNA virus by Tercero, J.C. (Pharmagen, Madrid, Spain), Dinman, J.D, Wickner, R.B

“…The MAK3 gene of Saccharomyces cerevisiae encodes an N-acetyltransferase whose acetylation of the N terminus of the L-A double-stranded RNA virus major coat…”
Get full text